Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Ophthalmology

Survivorship & Monitoring: Life After Initial Treatment

At a Glance

After CMV retinitis becomes inactive, CMV remains in the body and can return if immunity weakens. Regular dilated retinal exams, with imaging when appropriate, are essential because recurrence may be silent even when vision feels normal.

Reaching the point where your CMV retinitis is considered “inactive” or “healed” is a major milestone. However, because CMV is a virus that stays in your body for life, “healed” does not mean the risk is gone [1][2]. Survivorship involves a shift from intensive treatment to a long-term active surveillance strategy designed to catch a recurrence before it can do new damage [3][4].

Criteria for Stopping Maintenance Therapy

One of the most common questions is when you can stop taking daily antiviral pills (like valganciclovir). Doctors follow guidelines to ensure the virus is truly dormant and your immune system is strong enough to act as a permanent “guard” [5]. Blood CMV PCR alone should not determine this decision.

  • For HIV Patients: Guidance commonly uses completely inactive retinitis for an adequate minimum treatment period (often 3 to 6 months) alongside CD4 recovery above 100 cells/µL for at least 3 months on effective antiretroviral therapy (ART) [5][6].
  • For Transplant Patients: The rules are more individualized and do not use a single CD4 rule [7]. Transplant decisions depend on transplant type, CMV serostatus, current immunosuppression, immune recovery, and clinical course [8][9]. They may require prolonged secondary prophylaxis. Only the treating team should stop therapy.

The Danger of “Silent” Recurrence

The most important thing to remember in the years following your diagnosis is that a recurrence can be asymptomatic (no symptoms) [10][11]. Because the virus often attacks the edges of the retina first, you may not notice any blurring or spots even if the disease has returned [12][13].

  • Recurrence Rates: In some studies of transplant patients, the virus returned in about 21% of cases, often several months after the initial infection was controlled [3].
  • Risk Factors: You are at higher risk for recurrence if your immune system weakens again, if you had a large area of infection originally, or if you develop neutropenia (low white blood cells) [14][15].

Your Long-Term Monitoring Toolkit

Regular eye exams are your best defense. During these visits, your retina specialist will use a variety of high-tech tools to map your retina and check for changes:

  • Dilated Fundus Exam: The “gold standard.” The doctor uses drops to widen your pupils and manually inspects every corner of your retina [16].
  • Ultra-Widefield Photography (UWF): This specialized camera captures a wide view of your retina [17]. It is excellent for spotting “satellite lesions” or new activity at the edges of your vision [17][18]. However, it is an adjunct and cannot replace a dilated indirect examination, as eyelids or anatomy can obscure lesions.
  • Optical Coherence Tomography (OCT): This creates a detailed 3D “map” of your retina’s layers [19]. It is the best tool for finding Cystoid Macular Edema (swelling) or other structural changes that could affect your central vision [20][19].
  • Fundus Autofluorescence (FAF): A type of imaging that detects patterns of fluorescence from retinal pigments to support assessment of lesion extent, though it does not independently identify a reliably active border [18][21].

A Lifetime Surveillance Schedule

While every patient is different, surveillance schedules are structured as clinician-determined minimums based on your risk:

  • During Active Disease/Induction: Exams may occur every 1 to 2 weeks [4][22].
  • During Maintenance (Stable): Intervals differ based on immune status, often every 1 to 3 months [23][24].
  • Post-Treatment (Immune Recovered): For HIV patients, protocols often use approximately three-month ophthalmic surveillance initially, while transplant follow-up must be highly individualized [3][25]. Any renewed immunosuppression or immune decline warrants prompt reassessment.

Living with the fear of a “relapse” can be exhausting. However, by staying consistent with your immune-system medications and your eye exams, you are doing everything possible to ensure that if the virus does wake up, you will catch it before it can damage your sight [23][26].

Common questions in this guide

When can maintenance antiviral treatment stop after CMV retinitis?
For people with HIV, clinicians commonly consider stopping maintenance treatment after the retinitis has been completely inactive for about 3 to 6 months and the CD4 count has remained above 100 cells/µL for at least 3 months on effective antiretroviral therapy. A blood CMV PCR result alone should not determine this decision. For transplant patients, the timing is individualized and may include prolonged secondary prophylaxis, so only the treating team should stop therapy.
Can CMV retinitis come back without causing symptoms?
Yes. A recurrence can be asymptomatic, and CMV may first affect the edges of the retina where blurring or spots are not noticeable. Regular retinal examinations remain important even when your vision feels normal.
How often are eye exams needed after CMV retinitis treatment?
The schedule depends on disease activity and immune status. Exams may be needed every 1 to 2 weeks during active disease, every 1 to 3 months during stable maintenance, and about every 3 months initially after treatment in people with HIV who have recovered immunity. Transplant follow-up is individualized, and any renewed immunosuppression or immune decline calls for prompt reassessment.
What tests monitor CMV retinitis after it becomes inactive?
A dilated fundus examination is the main monitoring test because it lets the clinician inspect the entire retina. Ultra-widefield photography can add a broad view, but it does not replace a dilated examination; OCT can detect retinal swelling and structural changes, while FAF can help assess the extent of lesions. These tests are selected and interpreted by your eye specialist.
Who has a higher risk of CMV retinitis recurrence?
Risk is higher when the immune system weakens again, including with renewed immunosuppression or immune decline. A large area of infection at the initial diagnosis and neutropenia, or a low white blood cell count, can also increase concern for recurrence.
What should I do if my immune system weakens after CMV retinitis treatment?
Contact your treating team or eye specialist promptly if you start medicines that suppress immunity, become ill, or are told that your immune function has declined. You may need an earlier screening examination because recurrence can occur before noticeable vision changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current CD4 count or immune recovery marker, and has it been stable enough for the recommended 3 to 6 months?
  2. 2.Based on the appearance of my retinal scars, do I meet the '6 months of inactivity' rule to consider stopping maintenance therapy?
  3. 3.If we stop my antiviral medication, how often will I need dilated eye exams to check for an asymptomatic recurrence?
  4. 4.Can we use ultra-widefield photography at my next visit to ensure there are no new 'satellite lesions' at the far edges of my retina?
  5. 5.Am I at higher risk for 'late' complications like new blood vessel growth (neovascularization) in my healed areas?
  6. 6.If my immune system weakens again in the future (due to new medications or illness), how quickly should I return for a screening exam?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Sleepless latency of human cytomegalovirus.

    Poole E, Sinclair J

    Medical microbiology and immunology 2015; (204(3)):421-9 doi:10.1007/s00430-015-0401-6.

    PMID: 25772624
  2. 2

    Clinical manifestations and immune markers of non-HIV-related CMV retinitis.

    Passarin O, Hoogewoud F, Manuel O, Guex-Crosier Y

    BMC infectious diseases 2024; (24(1)):787 doi:10.1186/s12879-024-09653-x.

    PMID: 39107686
  3. 3

    Analysis of Clinical Characteristics of Patients with Recurrent Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation.

    Wang X, Lu Y, Li H, et al.

    Journal of personalized medicine 2023; (13(4)) doi:10.3390/jpm13040639.

    PMID: 37109025
  4. 4

    Prognostic factors of cytomegalovirus retinitis after hematopoietic stem cell transplantation.

    Kim JY, Hong SY, Park WK, et al.

    PloS one 2020; (15(9)):e0238257 doi:10.1371/journal.pone.0238257.

    PMID: 32877457
  5. 5

    International consensuses and guidelines on diagnosing and managing cytomegalovirus (CMV) retinitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Professors of Ophthalmology (AAPPO) and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII).

    Hwang DK, Ng DSC, Qian Z, et al.

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2025; (14(5)):100248 doi:10.1016/j.apjo.2025.100248.

    PMID: 41038280
  6. 6

    Long-term Outcomes of Cytomegalovirus Retinitis in the Era of Modern Antiretroviral Therapy: Results from a United States Cohort.

    Jabs DA, Ahuja A, Van Natta ML, et al.

    Ophthalmology 2015; (122(7)):1452-63.

    PMID: 25892019
  7. 7

    Cytomegaloviral Retinitis in a Heart Transplant Patient: Case Report and Review of the Literature.

    Janicka-Maszke Z, Konopa J, Ślizień M, et al.

    Transplantation proceedings 2022; (54(4)):1158-1166 doi:10.1016/j.transproceed.2022.02.068.

    PMID: 35760629
  8. 8

    Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.

    Razonable RR

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2023; (29(9)):1144-1149 doi:10.1016/j.cmi.2023.03.020.

    PMID: 36963566
  9. 9

    CYTOMEGALOVIRUS RETINITIS WITH BELATACEPT IMMUNOSUPPRESSION.

    Fan J, Gong D, Truong C, et al.

    Retinal cases & brief reports 2022; (16(2)):199-203 doi:10.1097/ICB.0000000000000928.

    PMID: 31568220
  10. 10

    Cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation under cytomegalovirus antigenemia-guided active screening.

    Mori T, Kikuchi T, Koh M, et al.

    Bone marrow transplantation 2021; (56(6)):1266-1271 doi:10.1038/s41409-020-01176-8.

    PMID: 33311594
  11. 11

    Cytomegalovirus retinitis in hospitalized people living with HIV in the late antiretroviral therapy era in São Paulo, Brazil.

    Bogoni G, Lucas Júnior RM, Reis Schneider GA, et al.

    International journal of STD & AIDS 2023; (34(1)):48-53 doi:10.1177/09564624221135294.

    PMID: 36259434
  12. 12

    Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment.

    Zhang J, Kamoi K, Zong Y, et al.

    Viruses 2024; (16(9)) doi:10.3390/v16091427.

    PMID: 39339903
  13. 13

    "For your eyes only": ophthalmic complications following lung transplantation.

    Dhal U, Raju S, Singh AD, Mehta AC

    Journal of thoracic disease 2018; (10(11)):6285-6297 doi:10.21037/jtd.2018.09.156.

    PMID: 30622804
  14. 14

    Predictors for Recurrence of Cytomegalovirus Retinitis in HIV-Negative Patients.

    Tungsattayathitthan U, Singcanvanit R, Choopong P, et al.

    Ocular immunology and inflammation 2024; (32(5)):493-500 doi:10.1080/09273948.2023.2170250.

    PMID: 36749945
  15. 15

    Risk factors for the long-term prognosis and recurrence of HIV-negative cytomegalovirus retinitis in North China.

    Shi YH, Wang H, Kang H, et al.

    International journal of ophthalmology 2022; (15(10)):1634-1640 doi:10.18240/ijo.2022.10.11.

    PMID: 36262853
  16. 16

    Evidence and Consensus-Based Imaging Guidelines in Cytomegalovirus Retinitis: Multimodal Imaging in Uveitis (MUV) Task Force - Report 15.

    Leal I, Agarwal A, Berkenstock M, et al.

    Ophthalmology. Retina 2026; doi:10.1016/j.oret.2026.05.004.

    PMID: 42119730
  17. 17

    Ultra-widefield retinal imaging for early detection of asymptomatic cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation: a prospective pilot feasibility study.

    Moll-Udina A, Pedraza A, Miguel-Escuder L, et al.

    Journal of ophthalmic inflammation and infection 2026; (16(1)).

    PMID: 42047905
  18. 18

    Ultra-Widefield Fundus Autofluorescence in Cytomegalovirus Retinitis.

    Tadepalli S, Bajgai P, Dogra M, et al.

    Ocular immunology and inflammation 2020; (28(3)):446-452 doi:10.1080/09273948.2019.1595671.

    PMID: 31136217
  19. 19

    SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN MACULA-INVOLVING CYTOMEGALOVIRUS RETINITIS.

    Gupta MP, Patel S, Orlin A, et al.

    Retina (Philadelphia, Pa.) 2018; (38(5)):1000-1010 doi:10.1097/IAE.0000000000001644.

    PMID: 28376042
  20. 20

    OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN CYTOMEGALOVIRUS RETINITIS: A Longitudinal Study.

    Invernizzi A, Agarwal A, Ravera V, et al.

    Retina (Philadelphia, Pa.) 2018; (38(1)):108-117 doi:10.1097/IAE.0000000000001503.

    PMID: 28145973
  21. 21

    Spectral domain optical coherence tomography and fundus autofluorescence findings in cytomegalovirus retinitis in HIV-infected patients.

    Yashiro S, Nishijima T, Yamamoto Y, et al.

    Japanese journal of ophthalmology 2018; (62(3)):373-389 doi:10.1007/s10384-018-0574-9.

    PMID: 29445945
  22. 22

    Successful treatment of cytomegalovirus retinitis with oral/intravitreal antivirals in HIV-negative patients with lymphoma.

    Tasiopoulou A, Urzua CA, Lightman S

    Eye (London, England) 2023; (37(9)):1895-1903 doi:10.1038/s41433-022-02267-0.

    PMID: 36192634
  23. 23

    Diagnostic Utility of Ocular Symptoms and Vision for Cytomegalovirus Retinitis.

    Liu Y, Chen AS, Kamphaengkham S, et al.

    PloS one 2016; (11(10)):e0165564 doi:10.1371/journal.pone.0165564.

    PMID: 27788232
  24. 24

    Risk factors for ocular complications in HIV/AIDS patients: a retrospective analysis of ophthalmology consultations in a tertiary hospital in Central China.

    Zhang R, Zheng T, Chen X, et al.

    BMC ophthalmology 2026; (26(1)).

    PMID: 42174527
  25. 25

    Proliferative Retinopathy in Non-human Immunodeficiency Virus CMV Retinitis.

    Puri P, Kumar V

    Ocular immunology and inflammation 2024; (32(5)):501-504 doi:10.1080/09273948.2023.2219311.

    PMID: 37290062
  26. 26

    Spectrum of Newly Diagnosed Cytomegalovirus Retinitis in a Developing Country in the HAART Era.

    Singh SR, Dogra M, Kaur S, et al.

    Ocular immunology and inflammation 2020; (28(1)):119-125 doi:10.1080/09273948.2018.1538460.

    PMID: 30395753

This page explains long-term monitoring after CMV retinitis for educational purposes and does not replace medical advice. Your eye specialist and infectious disease or transplant team should decide when treatment can change and how often you need exams.

Get notified when new evidence is published on Cytomegalovirus retinitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.